Cargando…
Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma
The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced changes in the tumor. To this end, comparative proteomic profiling of tumor tissue samples from treatment‐naïve (TN, n = 20) and NA...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812839/ https://www.ncbi.nlm.nih.gov/pubmed/36400567 http://dx.doi.org/10.1002/1878-0261.13344 |
_version_ | 1784863819898552320 |
---|---|
author | Amrutkar, Manoj Verbeke, Caroline S. Finstadsveen, Anette Vefferstad Dorg, Linda Labori, Knut Jørgen Gladhaug, Ivar P. |
author_facet | Amrutkar, Manoj Verbeke, Caroline S. Finstadsveen, Anette Vefferstad Dorg, Linda Labori, Knut Jørgen Gladhaug, Ivar P. |
author_sort | Amrutkar, Manoj |
collection | PubMed |
description | The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced changes in the tumor. To this end, comparative proteomic profiling of tumor tissue samples from treatment‐naïve (TN, n = 20) and NAT‐treated (n = 22) PDACs was performed. Differentially expressed proteins were identified and correlation with overall survival (OS) was performed. Tumors were also examined for histopathological changes and expression of cancer stem cell (CSC) markers. Serum from 33 matched patients was analyzed for metabolic markers. Cytotoxicity, proliferation, and expression of CSC markers were assessed in chemoresistant Panc‐1 and Mia PaCa‐2 cells. Of the 2265 proteins identified, 227 and 144 proteins showed significantly altered expression and differential phosphorylation, respectively, in NAT compared with TN samples. The majority of these were metabolism‐related proteins, and 14 of these correlated moderately with OS. NAT‐treated tumors and chemoresistant cancer cells showed increased expression of CSC markers. Serum ALDH1A1 was higher in NAT compared with TN. Differentially phosphorylated proteins were mainly involved in cytoskeleton organization, cell locomotion, motility, and migration, and 17 of these showed a strong positive correlation with OS. This study provides evidence of the effects of NAT on PDAC metabolism at both the tumor and the systemic levels. NAT‐treated tumors showed significantly lower expression of metabolic proteins, and patients who underwent NAT showed reduced serum lactate and high‐density lipoprotein‐cholesterol. Lastly, cancer cells that survived cytotoxic treatment expressed higher CSC markers, both in vivo and in vitro. |
format | Online Article Text |
id | pubmed-9812839 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98128392023-01-05 Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma Amrutkar, Manoj Verbeke, Caroline S. Finstadsveen, Anette Vefferstad Dorg, Linda Labori, Knut Jørgen Gladhaug, Ivar P. Mol Oncol Research Articles The modest clinical benefits of neoadjuvant chemotherapy (NAT) in pancreatic ductal adenocarcinoma (PDAC) are associated with a lack of robust data on treatment‐induced changes in the tumor. To this end, comparative proteomic profiling of tumor tissue samples from treatment‐naïve (TN, n = 20) and NAT‐treated (n = 22) PDACs was performed. Differentially expressed proteins were identified and correlation with overall survival (OS) was performed. Tumors were also examined for histopathological changes and expression of cancer stem cell (CSC) markers. Serum from 33 matched patients was analyzed for metabolic markers. Cytotoxicity, proliferation, and expression of CSC markers were assessed in chemoresistant Panc‐1 and Mia PaCa‐2 cells. Of the 2265 proteins identified, 227 and 144 proteins showed significantly altered expression and differential phosphorylation, respectively, in NAT compared with TN samples. The majority of these were metabolism‐related proteins, and 14 of these correlated moderately with OS. NAT‐treated tumors and chemoresistant cancer cells showed increased expression of CSC markers. Serum ALDH1A1 was higher in NAT compared with TN. Differentially phosphorylated proteins were mainly involved in cytoskeleton organization, cell locomotion, motility, and migration, and 17 of these showed a strong positive correlation with OS. This study provides evidence of the effects of NAT on PDAC metabolism at both the tumor and the systemic levels. NAT‐treated tumors showed significantly lower expression of metabolic proteins, and patients who underwent NAT showed reduced serum lactate and high‐density lipoprotein‐cholesterol. Lastly, cancer cells that survived cytotoxic treatment expressed higher CSC markers, both in vivo and in vitro. John Wiley and Sons Inc. 2022-12-05 /pmc/articles/PMC9812839/ /pubmed/36400567 http://dx.doi.org/10.1002/1878-0261.13344 Text en © 2022 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Amrutkar, Manoj Verbeke, Caroline S. Finstadsveen, Anette Vefferstad Dorg, Linda Labori, Knut Jørgen Gladhaug, Ivar P. Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title | Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title_full | Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title_fullStr | Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title_full_unstemmed | Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title_short | Neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
title_sort | neoadjuvant chemotherapy is associated with an altered metabolic profile and increased cancer stemness in patients with pancreatic ductal adenocarcinoma |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9812839/ https://www.ncbi.nlm.nih.gov/pubmed/36400567 http://dx.doi.org/10.1002/1878-0261.13344 |
work_keys_str_mv | AT amrutkarmanoj neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma AT verbekecarolines neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma AT finstadsveenanettevefferstad neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma AT dorglinda neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma AT laboriknutjørgen neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma AT gladhaugivarp neoadjuvantchemotherapyisassociatedwithanalteredmetabolicprofileandincreasedcancerstemnessinpatientswithpancreaticductaladenocarcinoma |